|
|
| | TAFLUPOSIDE Basic information |
| Product Name: | TAFLUPOSIDE | | Synonyms: | TAFLUPOSIDE;Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 5-[3,5-dimethoxy-4-(phosphonooxy)phenyl]-9-[[4,6-O-(1R)-ethylidene-2,3-bis-O-[(2,3,4,5,6-pentafluorophenoxy)acetyl]-β-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-, (5R,5aR,8aR,9S)-;F 11782;F-11782;F11782 | | CAS: | 179067-42-6 | | MF: | C45H35F10O20P | | MW: | 1116.71 | | EINECS: | | | Product Categories: | | | Mol File: | 179067-42-6.mol |  |
| | TAFLUPOSIDE Chemical Properties |
| density | 1.71±0.1 g/cm3(Predicted) | | pka | 1.13±0.50(Predicted) |
| | TAFLUPOSIDE Usage And Synthesis |
| Uses | Tafluposide (F-11782) is a DNA topoisomerase inhibitor. Tafluposide has antitumor activity[1]. | | References | [1] Sargent JM, et al. Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs. 2003 Jul;14(6):467-73. DOI:10.1097/00001813-200307000-00013 |
| | TAFLUPOSIDE Preparation Products And Raw materials |
|